Inhibikase Therapeutics Inc (IKT)

Jun 04, 2026

IKT Technical Analysis | Trend, Signals & Chart Patterns | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Jun 04, 2026

May 28, 2026

Inhibikase Therapeutics (IKT) Recovers 3.5% as Buyers Defend Key Support LevelMAMA Signal - The Legal Advocate

May 28, 2026

May 27, 2026

Inhibikase Therapeutics (IKT) Holds Near Support Amid Narrow Trading RangeScalping Stock Signals - The Legal Advocate

May 27, 2026

May 25, 2026

Inhibikase Therapeutics (IKT) Dips 2.87% as Stock Approaches Critical Support at $1.61RSI Oversold Picks - The Legal Advocate

May 25, 2026

May 22, 2026

Inhibikase Therapeutics (IKT) Faces Selling Pressure as Stock Retreats to $1.69Parabolic SAR - Newser

May 22, 2026

May 22, 2026

Inhibikase Therapeutics (IKT) Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Takes Center StageShared Momentum Picks - Newser

May 22, 2026

May 22, 2026

IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 22, 2026

May 22, 2026

Inhibikase Gains EU Clearance for Global PAH Trial - MyChesCo

May 22, 2026

May 22, 2026

Inhibikase Therapeutics, Inc. (IKT) Competitors - Meyka

May 22, 2026

May 20, 2026

IKT Stock Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

May 20, 2026

May 20, 2026

Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 By Investing.com - Investing.com Nigeria

May 20, 2026

May 19, 2026

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

May 19, 2026

May 19, 2026

Cantor Fitzgerald Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $4 - Moomoo

May 19, 2026

May 19, 2026

Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 - Investing.com India

May 19, 2026

May 16, 2026

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT) - The Globe and Mail

May 16, 2026

May 16, 2026

BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo

May 16, 2026

May 15, 2026

ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan

May 15, 2026

May 15, 2026

Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan

May 15, 2026

May 15, 2026

Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan

May 15, 2026

May 15, 2026

Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan

May 15, 2026

May 15, 2026

Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo

May 15, 2026

May 14, 2026

Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent

May 14, 2026

May 14, 2026

Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors - TipRanks

May 14, 2026

May 12, 2026

Is Inhibikase Therapeutics (IKT) Fairly Valued After Q1 2026 EPS - GuruFocus

May 12, 2026

May 12, 2026

Inhibikase Advances PAH Drug with Global Phase 3 Trial Launch - BriefGlance

May 12, 2026

May 12, 2026

Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum - ChartMill

May 12, 2026

May 12, 2026

Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2026

May 12, 2026

Inhibikase (NASDAQ: IKT) deepens Q1 loss as pivotal PAH trial advances globally - Stock Titan

May 12, 2026

May 12, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

INHIBIKASE THERAPEUTICS ($IKT) Releases Q1 2026 Earnings - Quiver Quantitative

May 12, 2026

May 12, 2026

Inhibikase (NASDAQ: IKT) advances IMPROVE-PAH as Q1 2026 loss widens - Stock Titan

May 12, 2026

May 12, 2026

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - The Manila Times

May 12, 2026

May 12, 2026

Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension - TipRanks

May 12, 2026

May 09, 2026

Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat

May 09, 2026

May 08, 2026

What XXxs fundamentals reveal about its future (Rallies) 2026-05-08AI Powered Stock Picks - Newser

May 08, 2026

May 08, 2026

Inhibikase Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

May 08, 2026

May 05, 2026

How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - newser.com

May 05, 2026

May 01, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

May 01, 2026

May 01, 2026

IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Quarterly Profit Report - newsline.com

May 01, 2026

Apr 30, 2026

[DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan

Apr 30, 2026

Apr 30, 2026

[ARS] Inhibikase Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Apr 29, 2026

Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossSpecial Dividend - newser.com

Apr 29, 2026

Apr 22, 2026

IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 20, 2026

Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan

Apr 20, 2026

Apr 19, 2026

Inhibikase enrolls first patient in phase 3 PAH trial - MSN

Apr 19, 2026

Apr 18, 2026

Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026